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MaBACKGROUND Physiological cardiac adaptation to regular exercise, including biventricular dilation and T-wave
inversion (TWI), may create diagnostic overlap with arrhythmogenic right ventricular cardiomyopathy (ARVC).
OBJECTIVES The goal of this study was to assess the accuracy of diagnostic criteria for ARVC when applied to athletes
exhibiting electrocardiographic TWI and to identify discriminators between physiology and disease.
METHODS The study population consisted of athletes with TWI (n ¼ 45), athletes without TWI (n ¼ 35), and ARVC
patients (n ¼ 35). Subjects underwent electrocardiography (ECG), signal-averaged electrocardiography (SAECG),
echocardiography, cardiac magnetic resonance imaging (CMRI), Holter monitoring, and exercise testing.
RESULTS There were no electrical, structural, or functional cardiac differences between athletes exhibiting TWI and
athletes without TWI. When athletes were compared with ARVC patients, markers of physiological remodeling included
early repolarization, biphasic TWI, voltage criteria for right ventricular (RV) or left ventricular hypertrophy, and
symmetrical cardiac enlargement. Indicators of RV pathology included the following: syncope; Q waves or precordial
QRS amplitudes <1.8 mV; 3 abnormal SAECG parameters; delayed gadolinium enhancement, RV ejection
fraction #45%, or wall motion abnormalities at CMRI; >1,000 ventricular extrasystoles (or >500 non-RV outﬂow
tract) per 24 h; and symptoms, ventricular tachyarrhythmias, or attenuated blood pressure response during exercise.
Nonspeciﬁc parameters included the following: prolonged QRS terminal activation; #2 abnormal SAECG parameters;
RV dilation without wall motion abnormalities; RV outﬂow tract ectopy; and exercise-induced T-wave
pseudonormalization.
CONCLUSIONS TWI and balanced biventricular dilation are likely to represent benign manifestations of training in
asymptomatic athletes without relevant family history. Diagnostic criteria for ARVC are nonspeciﬁc in such individuals.
Comprehensive testing using widely available techniques can effectively differentiate borderline cases.
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AB BR E V I A T I O N S
AND ACRONYM S
ARVC = arrhythmogenic right
ventricular cardiomyopathy
CMRI = cardiac magnetic
resonance imaging
ECG = electrocardiography
EDV = end-diastolic volume
LV = left ventricle
LVH = left ventricular
hypertrophy
RBBB = right bundle branch
block
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2703I ndividuals engaging in regular, intensive sport-ing activity frequently demonstrate a constella-tion of electrical and structural cardiac
alterations that are collectively described as the “ath-
lete’s heart.” Although such training-induced
changes are generally considered physiological and
benign (1), they occasionally overlap with phenotypic
features of inherited cardiomyopathies, in which
vigorous exercise is associated with an increased
risk of sudden cardiac death (SCD) (2,3). Physiological
remodeling of the athlete’s right ventricle (RV) may
mimic changes observed in arrhythmogenic right
ventricular cardiomyopathy (ARVC) (4), which isSEE PAGE 2712 RV = right ventricle
RVH = right ventricular
hypertrophy
RVOT = right ventricular
outﬂow tract
SAECG = signal-averaged
electrocardiography
SCD = sudden cardiac death
TFC = Task Force Criteria
TWI = T-wave inversion
V-Ampmax = maximal QRS
amplitude in the precordial
leads
VE = ventricular
extrasystole(s)
WMA = wall motion
abnormalityresponsible for as many as 22% of SCD in young ath-
letes (2). Accurate differentiation between physiolog-
ical and pathological RV remodeling is essential
because failure to identify the disease could jeopar-
dize a young life, whereas an inappropriate diagnosis
of ARVC may lead to an unnecessary exclusion from
sporting activity. Whereas diagnostic algorithms to
facilitate the differentiation between physiological
left ventricular (LV) hypertrophy and hypertrophic
cardiomyopathy are established, similar data are
lacking for the RV. Furthermore, diagnostic criteria
for ARVC are derived from patients with established
disease (5) and may therefore not be applicable to
low-risk individuals, such as athletes. The objectives
of the present study were to assess the accuracy of
current diagnostic criteria for ARVC when applied
to athletes exhibiting phenotypic overlap with the
condition and to identify clinical discriminators
between RV physiology and disease.
METHODS
SUBJECTS. All participants provided written consent,
and ethical approval was obtained from the local
research ethics committee in accordance with the
Declaration of Helsinki. In the United Kingdom, the
charity Cardiac Risk in the Young subsidizes cardio-
vascular evaluations for several elite sporting organi-
zations that mandate pre-participation screening of all
member athletes. The screening protocol consists of a
health questionnaire, physical examination, and 12-
lead electrocardiogram (ECG). In order to facilitate a
study group exhibiting diagnostic overlap with ARVC,
45 athletes with ECG T-wave inversion (TWI) were
recruited between 2011 and 2013 for further detailed
assessment (TWIþ athletes). The TWIþ athletes were
required to exhibit anterior or lateral TWI as a mini-
mum inclusion criterion, as per the 2010 Task Force
Criteria (TFC) for the diagnosis of ARVC (5). A cohort ofathleteswithout TWI (TWI– athletes),matched
for age, sex, ethnicity, and sporting category,
was recruited to act as a control group. The
athletic cohorts were between 14 and 35 years
of age and competed at international,
national, or regional levels. Sporting disci-
plines were categorized as predominantly
endurance or strength, and as high-dynamic/
high-static or non–high-dynamic/high-static
disciplines, according to accepted criteria (6).
Athletes with any previous history of cardiac
or pulmonary disease, systemic hypertension,
or diabetes mellitus were excluded. The ARVC
cohort consisted of patients between 14 and 35
years of age presenting to 2 U.K. tertiary car-
diac referral centers with a new diagnosis of
“deﬁnite” ARVC by 2010 TFC (5).
ASSESSMENT PROTOCOL. All study partici-
pants underwent resting ECG, signal-averaged
electrocardiography (SAECG), transthoracic
echocardiography, cardiac magnetic reson-
ance imaging (CMRI), and exercise testing, and
they were assessed with reference to the 2010
TFC (5). Tissue characterization of the RV wall
was not performed in any case. Genetic testing
was offered only to the ARVC patients.
12-LEAD ELECTROCARDIOGRAM. A stan-
dard 12-lead ECG was performed in the su-
pine position using either a MAC 5000 or
MAC 5500 digital resting ECG recorder (GE Medical
Systems, Milwaukee, Wisconsin). Measurements were
made using calipers. The normal frontal cardiac axis
was considered to be>–30, but<120. Left ventricular
hypertrophy (LVH) and right ventricular hypertrophy
(RVH) were deﬁned according to the Sokolow-Lyon
voltage criteria (LVH ¼ SV1 þ RV5/6 >3.5 mV; RVH ¼
RV1 þ SV5/6 >1.05 mV). TWI $–0.1 mV in 2 or more
contiguous leads was considered signiﬁcant. Deep
TWI was deﬁned as $–0.2 mV. Leads V1 to V4 were
subclassiﬁed as anterior precordial leads. Biphasic
T waves were deﬁned as those with components
above as well as below the PR-segment. TWI in leads V1
to V3 or beyond, in the absence of complete right
bundle branch block (RBBB), was considered a major
diagnostic criterion for ARVC. TWI in leads V1 to V2, or
V4, V5, or V6 was considered a minor diagnostic crite-
rion in the absence of complete RBBB, or in leads V1 to
V4 with complete RBBB. Partial right bundle branch
block was deﬁned as QRS duration >100 ms, but
<120 ms, with rSR0 morphology in lead V1 and qRS
in V6. Early repolarization was deﬁned as J-point
elevation $0.1 mV in 2 or more consecutive leads.
A novel index of maximal QRS amplitude in the
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sured from the peak of the R-wave to the nadir of
the S-wave (greatest single value in leads V1 to V6).
Additional ECG markers compatible with ARVC
were sought, including QRS terminal activation
duration $55 ms in leads V1, V2, or V3 and the epsilon
wave (5).
CARDIOVASCULAR IMAGING. Echocardiographic ex-
aminations were performed using the following
commercially available ultrasonography systems:
Vivid-I (GE Healthcare, Milwaukee, Wisconsin);
CX50 (Philips Medical, Bothell, Washington); or iE33
(Philips Medical). A complete echocardiographic
study of the left and right heart was performed ac-
cording to international guidelines (7,8). Echocar-
diographic studies were saved to compact disks as
numeric ﬁles to generate anonymity, and cardiac
measurements were repeated independently by an
experienced cardiologist (A.Z.) blinded to the iden-
tity of the subject. All RV measurements were made
from end-diastolic frames acquired with the breath
held in end expiration. A Philips Achiever 3.0-T
TX scanner (Amsterdam, the Netherlands) was
used for CMRI examinations. Delayed gadolinium
enhancement images were acquired 10 min after ad-
ministration of 0.2 mmol/kg intravenous gadolinium-
diethylenetriaminepentaacetate (Guerbet Dotarem,
Obex Medical Limited, Auckland, New Zealand) using
an inversion-recovery gradient echo sequence. Ven-
tricular volumes and function were measured using
standard techniques and analyzed using semi-
automated software (Extended MR workspace, Phi-
lips, Amsterdam, the Netherlands) (9). All imaging
measurements were recorded as absolute values and
were also indexed to body surface area according to the
DuBois-DuBois formula (10).
HOLTER MONITOR, SIGNAL-AVERAGED ECG, EXERCISE,
AND GENETIC TESTING. Twenty-four-hour ambula-
tory ECG recording (Lifecard 12 Holters, Spacelabs
Healthcare, Hawthorne, California) was used to detect
ventricular arrhythmias. Subjects were encouraged to
continue day-to-day activities including exercise
during monitoring. Upright treadmill stress testing
was performed using a standard Bruce protocol (11).
Subjects were exercised to volitional exhaustion.
T-wave pseudonormalization was categorized as
complete, partial (positive increase in T-wave axis
but persistent negative component), or absent. The
same machines used for standard ECG were used
according to accepted methodology for SAECG, with
the use of a 40-Hz high-pass bidirectional ﬁlter (12).
Late potentials were deﬁned as abnormal values
in $1 of the following parameters (in accordance withARVC TFC): duration of ﬁltered QRS complex >114 ms
(with QRS duration <110 ms on standard ECG);
duration of terminal QRS (with amplitude <40 mV)
>38 ms; and root mean square voltage of the terminal
40 ms of ﬁltered QRS <20 mV (5). Genetic analysis
was performed on consenting ARVC patients for 5
desmosomal gene mutations: desmocollin-2; desmo-
glein-2; desmoplakin; junctional plakoglobin; and
plakophillin-2 (13).
STATISTICAL ANALYSIS. The Kolmogorov-Smirnov
test was used to assess normality of distributions.
Group differences were tested using 1-way analysis of
variance (with Sidak post-hoc test) or the Kruskall-
Wallis test (with Dunn post-hoc test). The chi-square
or Fisher exact tests were used to assess propor-
tional differences between groups. Forward stepwise
binary logistic regression was used to create a 5-
variable model for differentiating physiological RV
remodeling from ARVC. Variables included were the
following: V-Ampmax (mV); presence of 3 abnormal
SAECG parameters (1 ¼ yes); presence of >500 ven-
tricular extrasystoles (VE) per 24 h (1 ¼ yes); total
exercise test duration (min); and echocardiographic
ratio of RV basal dimension in apical view/LV end-
diastolic dimension in parasternal long axis view
>0.9 (1 ¼ yes). Goodness of ﬁt was assessed using
Nagelkerke R-square test and Hosmer-Lemeshow
test. Receiver-operating characteristic curves were
used to assess the discriminatory power of the model.
Youden criterion was used to derive an optimal
diagnostic cutoff value. All analyses were performed
using SPSS software (version 20, Chicago, Illinois).
Values are expressed as mean  SD or percentages
as appropriate. Two-tailed p values <0.05 were
considered signiﬁcant.
RESULTS
DEMOGRAPHICS, SYMPTOMS, AND FAMILY HISTORY
OF ATHLETES AND ARVC PATIENTS. Athletes
competed in 12 sporting disciplines, predominantly
soccer (35.0%), athletics (12.5%), cycling (11.3%),
rugby (11.3%), and triathlon (11.3%). All athletes were
either Caucasian (71.3%) or black (Table 1). Almost
one-half of the ARVC cohort (48.6%) performed #2 h/
week of exercise. Two ARVC patients (5.7%)
performed $6 h/week of exercise, although none
were competitive athletes. Previous episodes of
vasovagal syncope were reported in 3 athletes (3.8%),
occurring in the context of concurrent injury or acute
illness. Two athletes (2.5%) reported previous epi-
sodes of nonexertional, pleuritic chest pain. None of
the athletes were symptomatic during exertion. After
independent review by 2 experienced cardiologists
TABLE 1 Background Demographics of Athletes and ARVC Patients
TWIþ Athletes
(n ¼ 45)
TWI- Athletes
(n ¼ 35)
ARVC Patients
(n ¼ 35) p Value
Age, yrs 21.8  6.2 21.6  5.4 27.2  7.4 <0.001*†
Male 82.2 80.0 65.7 0.19
White/Asian/black 68.9/0.0/31.1 74.3/0.0/25.7 68.6/22.9/8.6 <0.001*†
BSA, m2 1.9  0.2 2.0  0.3 1.9  0.3 0.85
Training, h/week 15.7  8.0 13.3  3.3 1.0  2.1 <0.001*†
Endurance 84.4 82.9 — 1.00
HDHS 26.7 31.4 — 0.80
Values are mean  SD or %. *Statistically signiﬁcant between TWIþ athletes and ARVC patients. †Statistically
signiﬁcant between TWI– athletes and ARVC patients.
ARVC ¼ arrhythmogenic right ventricular cardiomyopathy; BSA ¼ body surface area; HDHS ¼ high-dynamic/
high-static; TWI ¼ T-wave inversion; þ ¼ positive; – ¼ negative.
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press symptoms suggestive of underlying cardiovas-
cular pathology. None of the athletes revealed a
family history of cardiomyopathy or premature SCD.
The vast majority of the ARVC cohort had been
assessed in the context of family screening (40.0%),
unexplained syncope (25.7%), or out-of-hospital car-
diac arrest (20.0%). Signiﬁcant cardiovascular symp-
toms were reported by 71.4% of the ARVC patients,
most frequently syncope (exertional: 28.6%; at rest:
20.0%), palpitations (exertional: 17.1%; at rest: 17.1%),
and pre-syncope (exertional: 11.4%; at rest: 2.9%).
Comprehensive evaluation of ﬁrst-degree relatives of
the ARVC patients conﬁrmed familial disease in 57.1%
of cases, with a history of SCD in 25.7% of families.
More than one-half of the ARVC cohort (54.3%) was
found to harbor a known disease-causing mutation
(plakophillin-2 alone: 28.6%; plakophillin-2 and des-
moplakin: 11.4%; desmocollin-2: 8.6%; desmoplakin
alone: 2.9%; desmoglein-2: 2.9%; negative genetic
testing: 20.0%; untested: 25.7%). Comprehensive
phenotypic and genetic characterization of the ARVC
cohort is demonstrated in Online Tables 1 and 2.
CLINICAL EVALUATION OF ATHLETES AND ARVC
PATIENTS. Electrocard iogram. Voltage LVH and
RVH were more common, and there was a trend to-
ward a greater prevalence of left and right atrial
enlargement in athletes compared with ARVC pa-
tients (Table 2). Pathological Q waves were observed
in 8.6% of ARVC patients, but in none of the athletes.
V-Ampmax ranged from 1.8 to 7.3 mV in male athletes,
compared with 0.8 to 3.3 mV in male ARVC patients.
In female athletes, V-Ampmax ranged from 1.2 to 3.5
mV, compared with 1.1 to 3.0 mV in female ARVC
patients. Almost two-thirds of the ARVC cohort
(62.9%) demonstrated TWI at presentation (Table 2).
Nearly one-fourth of ARVC patients (22.9%) revealed
inferior TWI, which does not constitute part of the
2010 TFC (5). The distribution of TWI in athletes and
ARVC patients is demonstrated on a lead-by-lead
basis in Online Table 3. T-wave characteristics were
compared between TWIþ athletes (n ¼ 45) and TWIþ
ARVC patients (n ¼ 22). There were no differences
between these 2 groups with respect to the distribu-
tion and depth of TWI (anterior TWI: 77.8% vs. 90.9%,
p ¼ 0.31; lateral TWI: 40.0% vs. 18.2%, p ¼ 0.10;
inferior TWI: 33.3% vs. 36.4%, p ¼ 1.00; deep TWI:
62.2% vs. 50.0%, p ¼ 0.43). However, the majority of
TWIþ athletes exhibited biphasic T-wave morphology
with preceding convex ST-segment elevation,
compared with a minority of the TWIþ ARVC patients
(71.1% vs. 13.6%; p < 0.001), who revealed isoelectric
ST-segments in the majority of cases. Anterior and
lateral early repolarization was 3-fold to 4-fold morecommon, and inferior early repolarization was 9-fold
more common in athletes than in ARVC patients.
Epsilon waves were not observed in any study sub-
ject. The QRS terminal activation duration in V1 to V3
and the prevalence of partial RBBB did not differ
between athletes and ARVC patients. One ARVC
patient (2.9%) exhibited ventricular pre-excitation.
Echocard iography . Image quality was sufﬁcient for
96.5% of the echocardiographic indexes of the
2010 TFC to be successfully quantiﬁed. The TWIþ and
TWI– athletes did not differ in any biventricular
echocardiographic structural or functional parame-
ters (Table 3). Athletes exhibited greater LV cavity
dimensions and mass and superior indexes of LV
diastolic function than did ARVC patients. None of
the linear measurements of RV size differed between
athletes and ARVC patients, even after indexing for
body surface area. Mean RV wall thickness was
almost 2 mm greater in athletes than in ARVC
patients. Among measures of global systolic and dia-
stolic function, RV fractional area change and tissue
Doppler RV long-axis velocity were greater in athletes
than in ARVC patients; a cutoff value of RV fractional
area change #30% demonstrated high speciﬁcity
(89.1%) for ARVC (Central Illustration). Regional RV
wall motion abnormalities (WMA) were observed in
over one-half of the ARVC patients (51.4%), compared
with only 3 of the athletes (3.8%).
Card iac magnet ic resonance imaging . The TWIþ
and TWI– athletes did not differ in any biventricular
CMRI structural or functional parameters (Table 3).
Athletes exhibited greater LV volumes and LV mass
than ARVC patients did. RV volumes did not differ
between any of the groups, even after indexing for
body surface area. A ratio of RV to LV end-diastolic
volume (EDV) (RVEDV/LVEDV) >1.2 was, however,
highly speciﬁc for ARVC, as was RV ejection
fraction #45% (Central Illustration). Regional RV WMA
TABLE 2 ECG Data for Athletes and ARVC Patients
TWIþ Athletes
(n ¼ 45)
TWI- Athletes
(n ¼ 35)
ARVC Patients
(n ¼ 35) p Value
Heart rate, beats/min 55.9  11.1 62.7  10.9 70.4  12.0 <0.001*
PR-segment interval, ms 158.6  25.4 164.3  24.7 157.2  32.2 0.54
Axis,  55.4  32.3 51.0  32.6 51.5  50.2 0.85
QRS interval, ms 94.8  10.7 95.4  8.0 95.7  12.8 0.93
TAD (V1–V3), ms 49.6  11.0 48.0  11.0 49.7  13.3 0.80
V-Ampmax, mV 3.8  1.2 3.3  0.9 2.0  0.7 <0.001*†
QTc, ms 418.4  28.0 406.3  22.6 423.1  38.8 0.08
RAD 2.2 0.0 5.7 0.34
LAD 0.0 0.0 2.9 0.33
pRBBB 8.9 9.7 8.6 0.99
RVH 16.3 16.1 0.0 0.041*†
LVH 60.0 51.4 11.4 <0.001*†
RAE 11.1 15.6 0.0 0.07
LAE 17.8 9.4 2.9 0.10
Q waves 0.0 0.0 8.6 0.03*†
TWI 100.0 — 62.9 —
Anterior TWI 77.8 — 57.1 —
Lateral TWI 40.0 — 11.4 —
Inferior TWI 33.3 — 22.9 —
Deep TWI 62.2 — 31.4 —
Biphasic TWI 71.1 — 8.6 —
ST-segment depression 2.2 0.0 5.7 0.34
Anterior ER 90.9 81.8 22.9 <0.001*†
Inferior ER 25.6 27.3 2.9 0.014*†
Lateral ER 37.2 33.3 11.4 0.033*
VE 0.0 5.8 14.3 0.03*
Pre-excitation 0.0 0.0 2.9 0.32
Values are mean  SD or %. *Statistically signiﬁcant between TWIþ athletes and ARVC patients. †Statistically
signiﬁcant between TWI– athletes and ARVC patients.
ECG ¼ electrocardiography; ER ¼ early repolarization; LAD ¼ left axis deviation; LAE ¼ left atrial enlargement;
LVH ¼ left ventricular hypertrophy; pRBBB ¼ partial right bundle branch block; QTc ¼ corrected QT interval;
RAD ¼ right axis deviation; RAE ¼ right atrial enlargement; RVH ¼ right ventricular hypertrophy; TAD (V1–V3) ¼
terminal activation duration of QRS complex in leads V1 to V3; V-Ampmax ¼maximal amplitude of QRS complex in
precordial leads; VE ¼ ventricular extrasystole; other abbreviations as in Table 1.
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athletes with apparent echocardiographic RV WMA
demonstrated normal RV wall motion at CMRI.
Fourteen ARVC patients (40.0%) exhibited delayed
gadolinium enhancement (RV only: n ¼ 3; interven-
tricular septum only: n ¼ 4; LV only: n ¼ 4; biven-
tricular: n ¼ 3), whereas none of the athletes did. Nine
ARVC patients (25.7%) revealed LV abnormalities
(regional WMA with or without delayed gadolinium
enhancement), whereas none of the athletes did.
S ignal -averaged ECG. The TWIþ and TWI– athletes
did not differ in any SAECG parameters (Table 4). The
ARVC cohort exhibited 3 abnormal SAECG parameters
more frequently than either of the 2 athlete groups
did (TWIþ athletes: 6.7%; TWI– athletes: 0%; ARVC
patients: 25.7%; p ¼ 0.019).
Arrhythmias on 12- lead ECG and Holter moni tor .
Two athletes (2.5%, both TWI–) revealed VE of RV
outﬂow tract (RVOT) morphology on the resting ECG.Five ARVC patients (14.3%) exhibited VE on the ECG
(2 patients with a single RVOT VE; 1 patient with
3 RVOT VE; 1 patient with a single LV VE; and 1
patient with 6 biventricular VE). Both patients with
LV-origin VE were subsequently diagnosed with
biventricular ARVC. One asymptomatic patient
with mild biventricular ARVC and LV ﬁbrosis on CMRI
exhibited a single RVOT VE on an otherwise normal
ECG. The TWIþ and TWI– athletes did not differ in any
Holter monitoring parameters (Table 4). The ARVC
cohort revealed a greater burden of ventricular
ectopic activity compared with TWIþ and TWI–
athletes (1,642.0  2,204.2 vs. 25.5  128.6 vs.
45.1  148.0 VE/24 h, respectively). Two athletes
exhibited >500 VE/24 h (RVOT morphology). Seven
ARVC patients (20.0%) demonstrated sustained
or nonsustained ventricular tachycardia on Holter
monitoring, but none of the athletes did.
Exerc i se test ing . Cardiovascular symptoms were
present in 4 ARVC patients (11.4%) during exercise
testing (limiting chest pain: n ¼ 1; severe dyspnea:
n ¼ 1; pre-syncope: n ¼ 1; palpitations: n ¼ 1), but in
none of the athletes (Table 4). Less than one-half of the
ARVC patients (42.9%) were able to complete 12 min of
theBruceprotocol,whereas all of the athleteswere able
to. The majority of TWIþ athletes (73.3%) displayed
complete T-wave pseudonormalization during exer-
cise,whereas 40.0%ofARVCpatients did. Aproportion
of TWIþ athletes (13.3%) and TWIþ ARVC patients
(40.0%) failed to exhibit any degree of T-wave
pseudonormalization. Exercise-induced ST-segment
depressionwas observed in 3ARVCpatients (8.6%) and
innoneof theathletes. IsolatedVEduringexercisewere
observed in 8 athletes (10.0%), and the ectopic burden
did not increase from the resting state in any case.
In contrast, ventricular ectopic activity increased
during exercise in 11 ARVC patients (31.4%), with non-
sustained ventricular tachycardia in 4 cases (11.4%).
None of the athletes exhibited an attenuated systolic
blood pressure response to exercise (<20 mm Hg in-
crease), whereas 4 of the ARVC patients (11.4%) did.
Exercise-induced hypotension was observed in 1
ARVC patient (2.9%).
DIAGNOSTIC OVERLAP BETWEEN PHYSIOLOGICAL
RV REMODELING AND ARVC. After application of the
2010 TFC to all study subjects, almost all TWIþ ath-
letes fulﬁlled “possible” (51.1%) or “borderline”
(44.5%) criteria. All ARVC patients met “deﬁnite”
criteria, whereas the TWI– athletes were classiﬁed as
“normal” (88.2%) or “possible” ARVC (11.8%). Of
note, 3 athletes (3.75%) initially fulﬁlled echocardio-
graphic criteria, although CMRI disproved the pres-
ence of RV WMA in these individuals. By deﬁnition,
TABLE 3 Echocardiographic and CMRI Data for Athletes and ARVC Patients
TWIþ Athletes
(n ¼ 45)
TWI- Athletes
(n ¼ 35)
ARVC Patients
(n ¼ 35) p Value
Echocardiography
LAA, cm2 21.7  4.1 19.5  3.5 17.3  4.7 0.001*
LVEDD, mm 53.0  4.2 53.3  4.2 47.7  6.3 <0.001*†
Ao, mm 31.0  3.6 30.5  4.0 29.5  3.8 0.26
LVWT, mm 10.3  1.5 9.7  1.3 9.5  1.8 0.10
LVFS, % 35.1  5.0 34.6  5.0 32.8  8.6 0.30
LV E/A 2.2  0.6 2.0  0.6 1.8  0.6 0.013*
E0 lateral, cm/s 17.5  5.0 18.6  4.1 13.9  4.2 0.005*†
LVMI, g/m2 123.2  28.9 116.3  25.8 88.8  22.5 <0.001*†
RAA, cm2 19.5  4.3 18.3  4.7 16.7  4.1 0.05
RVEDA, cm2 27.7  5.4 26.3  4.7 24.2  5.0 0.028*
RVOTP, mm 30.4  4.6 29.8  4.6 30.2  6.6 0.90
RVOT1, mm 32.3  4.7 32.6  5.2 33.1  6.5 0.84
RVOT2, mm 23.0  3.0 23.8  3.2 22.8  5.2 0.58
RVD1, mm 43.3  4.7 42.4  4.9 41.7  6.1 0.43
RVD2, mm 34.2  5.3 33.5  4.5 32.2  5.9 0.32
RVD3, mm 89.3  8.5 86.9  8.5 84.7  11.0 0.14
RVOTP-i, mm/m2 16.0  2.7 15.8  2.6 15.5  2.5 0.81
RVOT1-i, mm/m2 17.0  2.6 17.5  2.8 17.4  2.7 0.78
RVWT, mm 4.9  1.0 4.8  1.0 3.1  1.2 <0.001*†
RVD1/LVEDD 0.82  0.07 0.80  0.09 0.88  0.15 0.011†
RVFAC, % 37.8  6.2 36.0  6.1 31.6  10.8 0.008*
RV S0, cm/s 13.5  2.7 13.3  2.1 11.8  2.9 0.044*
TAPSE, mm 21.2  3.7 21.7  3.9 20.6  5.4 0.67
RV E0, cm/s 12.7  3.4 14.4  3.8 10.9  3.3 0.005†
PASP, mm Hg 23.1  3.5 25.4  4.4 24.0  4.5 0.25
RV WMA 2.2 5.7 51.4 <0.001*†
CMRI
LVEDV, ml 193.8  40.9 206.3  40.6 142.5  42.6 <0.001*†
LVEDV-i, ml/m2 101.5  17.9 103.4  15.1 74.8  18.5 <0.001*†
LV mass, g 158.6  57.6 164.9  33.0 112.5  34.7 0.009*†
LV mass-i, g/m2 90.7  28.1 82.6  10.9 72.3  28.7 0.147
RVEDV, ml 202.8  42.3 211.3  40.6 175.8  71.5 0.10
RVEDV-i, ml/m2 107.0  18.6 106.9  15.1 96.3  36.4 0.32
RVEF, % 59.9  7.0 53.4  6.9 49.0  11.8 <0.001*
RVEDV/LVEDV 1.06  0.12 1.03  0.09 1.24  0.30 0.002*†
RV WMA 0.0 0.0 51.4 0.001*†
DGE 0.0 0.0 40.0 <0.001*†
LV involvement 0.0 0.0 25.7 0.001*†
Values are mean  SD or %. The sufﬁx “-i” indicates that the value has been indexed to body surface area.
*Statistically signiﬁcant between TWIþ athletes and ARVC patients. †Statistically signiﬁcant between TWI– ath-
letes and ARVC patients.
Ao ¼ aortic root dimension; CMRI ¼ cardiac magnetic resonance imaging; DGE ¼ delayed gadolinium
enhancement; E0 ¼ early myocardial relaxation velocity; E/A ¼ ratio of early to late diastolic inﬂow velocities;
LAA ¼ left atrial area; LV ¼ left ventricle; LVEDD ¼ left ventricular end-diastolic dimension; LVEDV ¼ left
ventricular end-diastolic volume; LVFS ¼ left ventricular fractional shortening; LVMI ¼ left ventricular mass
index; LVWT ¼ maximal left ventricular wall thickness; PASP ¼ pulmonary artery systolic pressure; RAA ¼ right
atrial area; RV ¼ right ventricle; RVD1 ¼ right ventricular basal dimension; RVD2 ¼ right ventricular mid-
ventricular dimension; RVD3 ¼ right ventricular longitudinal dimension; RVEDA ¼ right ventricular end-diastolic
area; RVEDV ¼ right ventricular end-diastolic volume; RVEF ¼ right ventricular ejection fraction; RVFAC ¼ right
ventricular fractional area change; RVOTP ¼ right ventricular outﬂow tract dimension (parasternal); RVOT1 ¼
proximal right ventricular outﬂow tract dimension; RVOT2 ¼ distal right ventricular outﬂow tract dimension;
RVWT ¼ right ventricular free wall thickness; S0 ¼ peak systolic velocity; TAPSE ¼ tricuspid annular plane systolic
excursion; WMA ¼ wall motion abnormality; other abbreviations as in Tables 1 and 2.
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2707all TWIþ athletes fulﬁlled repolarization criteria
(major: 55.6%; minor: 44.4%). The majority of ath-
letes (81.3%) met minor depolarization criteria, pri-
marily due to an abnormal SAECG. Two athletes
(2.5%) fulﬁlled minor arrhythmic criteria due to the
presence of >500 VE (of RVOT morphology) in 24 h.
One TWIþ athlete was erroneously diagnosed with
“deﬁnite” ARVC at initial presentation, due to ante-
rior TWI, RV dilation, and apparent RV WMA at
echocardiography, although subsequent CMRI
revealed normal wall motion. An additional compar-
ison was performed among all athletes (n ¼ 80),
phenotypically severe ARVC cases fulﬁlling “deﬁnite”
criteria even without considering family history
(n ¼ 24), and milder ARVC cases meeting “deﬁnite”
criteria due primarily to family history (n ¼ 11). The
results (Online Table 4) reveal considerable diag-
nostic overlap between athletic adaptation and ARVC,
even after controlling for patients with mild disease.
Finally, the following score for differentiating physi-
ological remodeling fromARVCwas derived: 1/(1þ e-z),
where z ¼ (27.349 þ 13.331 [presence of 3 abnormal
SAECG parameters] þ 9.992 [presence of >500 VE per
24 h] –3.068 [V-Ampmax] þ 5.537 [RV basal dimension
in apical view/LV end-diastolic dimension in para-
sternal long axis view >0.9] – 1.768 [exercise dura-
tion]). Nagelkerke R square value for the model was
0.918 andHosmer-Lemeshow test revealed a p value of
0.997. Receiver-operating characteristic analysis for
accurate diagnosis of ARVC demonstrated an area un-
der the curve of 0.993 using a cutoff value of >0.45
(95% conﬁdence interval: 0.979 to 1.00 [p < 0.001],
sensitivity: 96.3%, speciﬁcity: 100%, positive predic-
tive value: 100%, negative predictive value: 98.6%).
This model is the basis for the multivariable calcu-
lator for the differentiation between physiological
remodeling and arrhythmogenic right ventricular
cardiomyopathy provided in the Online Appendix.
DISCUSSION
COMPARISON BETWEEN TWID AND TWI– ATHLETES.
Comprehensive testing did not reveal any differ-
ences between TWIþ and TWI– athletes in any elec-
trical, structural, or functional cardiac parameters.
This ﬁnding supports the notion that TWI may
represent a benign manifestation of intensive train-
ing in the majority of asymptomatic athletes without
relevant family history. Furthermore, it serves as a
reference point that any differences observed be-
tween TWIþ athletes and ARVC patients in the pre-
sent study may be interpreted as being due to
athletic training in the former or cardiac pathology in
the latter.DIFFERENTIATION BETWEEN PHYSIOLOGICAL TWI
AND ARVC. Convent iona l patholog ica l markers
exh ib i t ing h igh accuracy . The study conﬁrms the
diagnostic power of certain established pathological
CENTRAL ILLUSTRATION Distribution of Values for Cardiovascular Imaging Parameters in Athletes and Patients With ARVC
Zaidi, A. et al. J Am Coll Cardiol. 2015; 65(25):2702–11.
The blue-shaded areas demonstrate values more likely to represent pathological cardiac remodeling. The dashed lines in A and B indicate current minor Task Force
Criteria (TFC) for arrhythmogenic right ventricular cardiomyopathy (ARVC). Values represent the following: (A) echocardiographic (Echo) right ventricular fractional area
change (RVFAC); (B) cardiac magnetic resonance imaging (CMRI) right ventricular ejection fraction (RVEF); and the (C) CMRI ratio of right ventricular end-diastolic
volume (RVEDV) to left ventricular end-diastolic volume (LVEDV).
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2708indicators, including syncope in the absence of cir-
cumstances (such as pain) clearly leading to reﬂex-
mediated changes in vascular tone or heart rate,
exercise-induced cardiovascular symptoms, a high
burden of ventricular ectopic activity, and sustained
or nonsustained ventricular arrhythmias. Markers of
myocardial ﬁbrosis and regional WMA at CMRI
also demonstrate potent discriminatory ability and
are likely to form the cornerstone of diagnosis in
phenotypically borderline cases (Figure 1).Convent iona l patholog ica l markers exh ib i t ing
poor accuracy . Several conventional pathological
markers appear to demonstrate poor accuracy in the ath-
letic setting. Consensus guidelines for ECG interpretation
in athletes suggest that TWI in $2 consecutive leads,
epsilon waves, prolonged QRS terminal activation dura-
tion in V1 to V3, reduced limb lead voltages, and VE with
left bundle branch block morphology and superior axis
should prompt further investigation for ARVC (14). We
have recently demonstrated that TWI and voltage RVH
TABLE 4 SAECG, Holter Monitor, and Exercise Data for Athletes and ARVC Patients
TWIþ Athletes
(n ¼ 45)
TWI-Athletes
(n ¼ 35)
ARVC Patients
(n ¼ 35) p Value
SAECG
FQRS, ms 123.9  17.7 117.3  8.7 118.9  16.4 0.30
HFLA <40 mV, ms 32.7  16.5 28.0  7.2 36.5  8.4 0.09
RMS40, mV 35.6  15.7 39.6  11.5 29.9  18.4 0.14
0 positive parameters 26.7 48.6 37.1 0.37
1 positive parameter 55.6 42.9 31.4 0.18
2 positive parameters 11.1 8.6 5.7 0.60
3 positive parameters 6.7 0.0 25.7 0.019*†
Holter monitor
VE/24 h 25.5  128.6 45.1  148.0 1,642.0  2,204.2 <0.001*†
VT episodes 0.0 0.0 20.0 <0.001*†
VT episodes, including
index event
0.0 0.0 48.6 <0.001*†
Exercise test
Exercise duration, min 17.1  3.4 16.2  3.3 10.4  3.7 <0.001*†
SBP rise, mm Hg 71.2  26.1 59.1  17.5 41.8  23.1 <0.001*†
SBP drop 0.0 0.0 2.9 0.185
VE, exertion 15.5 2.9 62.9 <0.001*†
VT, exertion 0.0 0.0 11.4 0.012*†
Pseudonormalization,
absent/partial/complete
13.3/13.3/73.3 — 40.0/20.0/40.0 0.038
ST-segment depression,
exertion
0.0 0.0 8.6 0.063
Symptoms 0.0 0.0 11.4 0.015*†
Values are mean  SD or %. *Statistically signiﬁcant between TWIþ athletes and ARVC patients. †Statistically
signiﬁcant between TWI– athletes and ARVC patients.
FQRS ¼ duration of ﬁltered QRS complex; HFLA <40 mV ¼ duration of high frequency low amplitude (less than
40 mV) signal; RMS40 ¼ root mean square voltage of the terminal 40 ms of the ﬁltered QRS complex; SBP ¼
systolic blood pressure; VE ¼ ventricular extrasystole; VT ¼ ventricular tachycardia; other abbreviations as
in Table 1.
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2709shouldbe interpretedwith caution inathletes, particularly
those of African/Afro-Caribbean origin, due to consider-
able diagnostic overlap with physiological adaptation
(4,15). In the present study, QRS terminal activation
duration failed to differentiate between athletic remodel-
ing and ARVC. This phenomenon probably reﬂects pro-
longed conduction through a physiologically enlargedRV,
further reﬂected in a high prevalence of partial RBBB and
SAECG abnormalities in athletes (4,16,17). The current
minorTFCof>500VE/24h fails to specifyVEmorphology,
attributing minor criteria to 2 healthy athletes with RVOT
ectopy in this study. Exercise-induced T-wave pseudo-
normalization, or lack thereof, is also a poor discriminator,
consistent with recent reports (18). The study also re-
inforces the nonspeciﬁc nature of RV dilation and/or low-
normal systolic function without regional WMA (4,19).
Finally, although advanced ARVC is usually associated
with ECG abnormalities (20), it is noteworthy that one-
third of our ARVC cohort exhibited a normal ECG, in
some cases with a severe structural phenotype.
Addit iona l patholog ica l markers exh ib i t ing h igh
accuracy . A number of disease markers additional to
current TFC were identiﬁed in the present study.
Pathological Q waves, which are known to correlate
with structural phenotype in ARVC (20), were
observed exclusively in our disease cohort and should
be considered abnormal unless proven otherwise.
Almost one-fourth of the ARVC cohort exhibited infe-
rior TWI, which does not feature in current diagnostic
criteria. A novel marker assessing precordial rather
than limb lead voltages was identiﬁed, such that
values for V-Ampmax<1.8 mV strongly favor pathology
in male subjects. Current recommendations advocate
further testing if $2 VE are present on the resting ECG
(14); however, we observed that a single VE might be
the only ECG manifestation of mild RV disease. The
current minor criterion of 1 abnormal SAECG param-
eter proved nonspeciﬁc. In contrast, 3 abnormal pa-
rameters revealed strong predictive accuracy for
ARVC.Novel ratio indicators of asymmetric ventricular
dilation (echocardiographic RV basal dimension in
apical view/LV end-diastolic dimension in parasternal
long axis view >0.9 or CMRI RVEDV/LVEDV >1.2) also
demonstrated high speciﬁcity for disease. Attenuated
blood pressure responses to exercise were seen
exclusively in ARVC patients, consistent with ﬁndings
in hypertrophic cardiomyopathy (21). Finally, it is
noteworthy that one-fourth of the ARVC cohort
exhibited regional WMA or delayed enhancement in
the LV, which, althoughwell reported in the literature,
does not form part of current diagnostic criteria (5).
Addit iona l markers suggest ive of phys io log ica l
remodel ing . Electrocardiographic markers, such as
early repolarization in any territory or biphasicTWI with preceding ST-segment elevation, appear
strongly indicative of physiological remodeling.
Voltage LVH and RVH were rarely observed in ARVC
patients, but they were common in athletes, lending
further support to training-induced adaptation. RV
dilation with normal regional wall motion and
concomitantly increased LV dimensions also suggests
physiological remodeling.
STUDY LIMITATIONS. Due to the rarity of the dis-
ease in youths, the ARVC cohort was small, was not
matched to the athletes for ethnicity, and was
slightly older than the athlete cohorts. Genetic
testing was only performed in ARVC patients;
hence, the TFC could not be applied comprehen-
sively to athletes. The ARVC cohort comprised pa-
tients who in some cases had advanced disease, and
none were professional athletes. Although the
enrollment of asymptomatic athletes with ARVC, or
athletes reporting cardiovascular symptoms, might
yield greater insight into the diagnostic “gray zone,”
the present study provides comprehensive pheno-
typic characterization, which should assist in the
FIGURE 1 Proposed Clinical Indicators to Assist in the Differentiation Between Athletic RV Remodeling and ARVC
Athlete’s RV
Consider Athlete’s RV
Voltage LVH on ECG
Distribution of TWI
Syncope (nonvasovagal)
Q waves
≥1 VE on resting ECG
RVWT ≤3 mm
RVFAC (echo) ≤30%
RVEF (CMRI) ≤45%
RV WMA or DGE (CMRI)
3 abnormal SAECG parameters
ETT duration <12 min
Increase in VE during ETT
NSVT / VT (Holter, ETT)
>500 VE / 24 h (unless all RVOT)
>1,000 VE / 24 h (any morphology)
SBP rise < 20 mm Hg or ↓BP on ETT
TWI + isoelectric ST-segment
Any exertional symptoms
+VE FHx (ARVC, SCD, genetics)
Depth of TWI
pRBBB
LAE on ECG
Lack of pseudonormalization 
RAE on ECG
RVFAC (echo) 31%–40%
Apical RV WMA at echo
0-2 abnormal SAECG parameters
TWI pseudonormalization on ETT
RV size (absolute or indexed)
QRS terminal activation time
Biphasic TWI
Convex STE + TWI
Inferior / lateral ER
RVD1/LVEDD ≤0.9 (echo)
RVEDV/LVEDV ≤1.2 (CMRI)
Voltage RVH on ECG
V-Ampmax >3.3 mV (male subjects)
V-Ampmax <1.8 mV (male subjects)
Poor Discriminators Consider ARVC
ARVC
TWI ± RV Dilation
Clinical differentiation between athletic RV remodeling and ARVC. ARVC ¼ arrhythmogenic right ventricular cardiomyopathy; BP ¼ blood
pressure; CMRI ¼ cardiac magnetic resonance imaging; DGE ¼ delayed gadolinium enhancement; ECG ¼ electrocardiogram; ER ¼ early
repolarization; ETT ¼ exercise tolerance test; FHx ¼ family history; LAE ¼ left atrial enlargement; LVEDD ¼ left ventricular end-diastolic
dimension; LVEDV ¼ left ventricular end-diastolic volume; LVH ¼ left ventricular hypertrophy; NSVT ¼ nonsustained ventricular tachycardia;
pRBBB ¼ partial right bundle branch block; RAE ¼ right atrial enlargement; RV ¼ right ventricle; RVD1 ¼ right ventricular basal dimension;
RVEDV ¼ right ventricular end-diastolic volume; RVEF ¼ right ventricular ejection fraction; RVFAC ¼ right ventricular fractional area change;
RVH ¼ right ventricular hypertrophy; RVOT ¼ right ventricular outﬂow tract; RVWT ¼ right ventricular wall thickness; RV WMA ¼ right
ventricular wall motion abnormality; SAECG ¼ signal-averaged electrocardiogram; SBP ¼ systolic blood pressure; SCD ¼ sudden cardiac death;
STE ¼ ST-segment elevation; TWI ¼ T-wave inversion; V-Ampmax ¼ maximal QRS amplitude in precordial leads; VE ¼ ventricular extrasystole;
VT ¼ ventricular tachycardia; WMA ¼ wall motion abnormality.
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2710differentiation between physiological and patho-
logical remodeling in athletes with incomplete dis-
ease expression. Whereas the multivariable score
derived from our data demonstrates excellent diag-
nostic performance, it was derived from studying
small numbers of subjects and requires validation in
larger cohorts. Finally, the cross-sectional study
design precludes the categorical exclusion of future
RV pathology in athletes with marked repolari-
zation anomalies, although the high prevalence of
TWI in athletic individuals favors physiological
remodeling.CONCLUSIONS
Electrocardiographic TWI and balanced biventricular
dilation are likely to represent benign manifestations of
intensive training in the majority of asymptomatic ath-
letes without relevant family history. Diagnostic criteria
for ARVC are nonspeciﬁc in such cases and may lead to
erroneous diagnoses. Low precordial ECG amplitudes,
unbalancedRVdilation,wallmotion abnormalities, a high
burden of ventricular extrasystoles, and abnormal re-
sponses to exercise testing are key markers of patho-
logical remodeling. Comprehensive testing using widely
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Healthy, ath-
letic individuals may exhibit electrocardiographic TWI, RV
enlargement, and ventricular late potentials. The current TFC
for ARVC may, therefore, erroneously suggest a diagnosis in
such individuals.
TRANSLATIONAL OUTLOOK: Studies on the basis of CMRI,
cardiopulmonary exercise testing, and molecular genetics may
improve diagnostic accuracy and clarify the differentiation be-
tween athletic adaptation and mild cardiomyopathy.
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2711available techniques can effectively differentiate pheno-
typically borderline cases.
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